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The mortality risk associated  
with higher hemoglobin:  
is the therapy to blame?
Mitchell H. Rosner1 and W. Kline Bolton1
Recent trials have demonstrated a trend for increased mortality 
when patients with end-stage renal disease (ESRD) or chronic kidney 
disease (CKD) are treated with erythropoietin-stimulating agents 
(ESAs) to hemoglobin levels higher than recommended (>13 g/dl). 
Recent studies suggest that higher doses of ESAs, in themselves, may 
be at least partly responsible for this mortality risk. This is important, 
as more than 90% of patients with ESRD and approximately 20% of 
patients with CKD receive ESAs. Two new studies address this.
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One of the greatest advances in the care 
of patients with either end-stage renal 
disease (ESRD) or chronic kidney dis-
ease (CKD) has been the introduction 
of erythropoietin analogues, also termed 
erythropoietin-stimulating agents (ESAs). 
These drugs have allowed patients to live 
with higher hemoglobin levels without the 
risk of recurrent blood transfusions and 
iron overload. At the same time, several 
studies have documented a substantial 
improvement in the quality of life when 
either ESRD or CKD patients have their 
anemia partially corrected.1 A logical 
question that arose in the management 
of kidney disease–associated anemia was 
whether normalization of hemoglobin 
levels rather than partial correction to the 
recommended National Kidney Founda-
tion Kidney Disease Outcomes Quality 
Initiative levels (11–12 g/dl) would be 
associated with improved outcomes. This 
question takes on increased meaning with 
the knowledge of the very high cardiovas-
cular mortality that is associated with both 
ESRD and CKD and the need to find ther-
apies that positively impact this problem.
Thus, it came as some surprise when 
three randomized controlled trials, 
the Normal Hematocrit Cardiac Trial 
(NHCT), the Correction of Hemoglobin 
and Outcomes in Renal Insufficiency 
(CHOIR) trial, and the Cardiovascular 
Risk Reduction by Early Anemia Treat-
ment with Epoetin β trial, all showed a 
consistent finding: an increase in all-cause 
mortality that trended to statistical signifi-
cance and ranged from 21% to 48% in the 
groups that were treated to higher hemo-
globin levels (generally above 13–13.5 g/
dl).2–4 Supporting the conclusions of the 
randomized controlled trials is a large 
observational study demonstrating the 
highest survival in ESRD patients with 
hemoglobin values between 12 and 13 g/
dl and a higher risk of mortality in those 
with hemoglobin values above 13 g/dl.5
What explains the mortality risk associ-
ated with treatment of patients to higher 
hemoglobin levels with ESAs? What off-
sets the theoretical advantage of increas-
ing oxygen delivery and improving cardiac 
hemodynamics to account for these find-
ings in multiple randomized controlled 
trials? As Fishbane and Besarab have 
discussed, there is probably no single 
operative mechanism but several inter-
acting causes. These potential causes are 
so intertwined that the data contained 
in the randomized controlled trials are 
unlikely to be able to give the etiological 
answer. These causes include comorbid-
ity of patients that often leads to difficulty 
attaining target hemoglobin (confounding 
by indication), increases in blood viscosity, 
increase in thrombogenesis, rises in blood 
pressure and blood volume, increased iron 
requirements, and the potential toxici-
ties of non-physiological doses of ESAs.6 
This last possibility was suggested in the 
observational study of Regidor et al., in 
which all-cause mortality increased with 
prescribed weekly ESA dosages in excess 
of 5,999 units per week (cardiovascular 
mortality increased with dosages in excess 
of 11,999 units per week).5 Other studies 
have also documented a higher risk in 
patients receiving higher doses of ESAs.7 
Now, two papers in this issue of Kidney 
International, one based on analysis from 
the CHOIR study, further raise the possi-
bility that high dosages of ESAs, especially 
in patients unable to reach hemoglobin 
targets, may have a deleterious effect.8,9
Szczech and colleagues report a post 
hoc analysis of data from CHOIR dem-
onstrating that in an unadjusted analysis, 
the inability to reach a target hemoglobin, 
as well as high-dose epoetin use (>20,000 
units per week), was associated with a sta-
tistically significant increased mortality.8 
At both 4 and 9 months of the study, in an 
adjusted model, only high-dose epoetin use 
was associated with increased risk of mor-
tality. The increased risk with higher-dose 
epoetin was seen in both the high- and 
low-hemoglobin groups. The relationship 
between epoetin dose and log hazard was 
J-shaped in the low-hemoglobin-target 
group and linear in the high-hemoglobin-
target group. The authors hypothesize that 
increasing doses of epoetin have a direct 
relationship to poor outcomes. This is 
especially true in patients who are unable 
to reach target hemoglobin levels and are 
thus subject to escalating doses of ESAs in 
an effort to reach a goal that may not be 
attainable. This suggests that limiting the 
total dose of ESAs, especially in those not 
reaching their target hemoglobin, may be 
a prudent strategy.
Can a study of this sort differenti-
ate between the failure to reach target 
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hemoglobin, which is, in part, due to 
serious comorbidities that independently 
impact mortality, and the use of higher 
doses of epoetin? As Szczech and col-
leagues point out,8 subjects not achiev-
ing their target hemoglobin experienced 
events at a higher rate, and the majority 
of these patients were in the high-hemo-
globin-target group (37.5% versus 4.7%). 
In fact, for subjects reaching their rand-
omized target hemoglobin, there was no 
increased risk associated with the higher 
hemoglobin goal. Importantly, the majority 
of high-dose epoetin use occurs in patients 
failing to make target hemoglobin. These 
are the very patients with chronic inflam-
mation or other conditions that may lead 
to increased mortality. Statistical modeling 
in this paper suggests that the most signifi-
cant factor is the high-dose epoetin use. 
Although the randomized nature of the 
trial allows for a more robust conclusion, 
as comorbid factors should be evenly dis-
tributed among both target-hemoglobin 
groups, this remains a secondary analysis 
of a trial designed to test target hemoglobin 
and not dose. Given that dose is a function 
of failure to respond, we may well ques-
tion whether any statistical modeling can 
really control for this confounding effect. 
In contrast to these results, in the NHCT 
there was no relationship between epoetin 
dose and the risk of mortality.2
Designing a trial that specifically 
assesses epoetin dose is a difficult task 
and will probably require the advent 
of non-epoetin ESA drugs. Recently, a 
carbamylated variant of erythropoietin 
(CEPO) that preferentially binds to the 
heterodimeric form of the erythropoietin 
receptor and does not stimulate erythro-
poiesis was described that may allow the 
design of studies to eventually dissociate 
erythropoietin’s increasing of hemoglobin 
from its other potential effects.10
If ESAs do indeed have toxic effects at 
higher doses, what accounts for these 
effects? ESAs have pleiotropic effects out-
side of the regulation of red blood cell pro-
duction.11 Receptors for erythropoietin 
are found in a variety of tissues, including 
the brain, retina, heart, kidney, smooth 
muscle cells, myoblasts, and vascular 
endothelium.11 This extra-erythropoietic 
signaling due to either endogenous or 
exogenous erythropoietin contributes to 
diverse processes such as wound healing, 
injury response, and angiogenesis. The 
cardiovascular effects of erythropoietin 
include the promotion and proliferation 
of endothelial cells, mobilization of bone 
marrow-derived endothelial progenitor 
cells, protection of the myocardium from 
ischemic injury, and perhaps modulation 
of cardiac function.10 Overall, the major-
ity of non-erythroid effects described for 
erythropoietin have promoted cellular 
survival, suggesting that the procoagulant 
and vasoactive effects may predominate 
in patients receiving high doses. Further-
more, when ESAs are delivered either sub-
cutaneously or intravenously at high doses, 
there is a rapid rise in serum erythropoietin 
levels followed by a rapid decline. Hypo-
thetically, these unique kinetics may cause 
potential harm. Another possible explana-
tion is proposed in a second article in this 
issue. Keithi-Reddy and colleagues report 
that anemic CKD patients have higher lev-
els of the proinflammatory cytokine tumor 
necrosis factor-α, and a trend to higher 
interleukin-6 and interleukin-8 levels.9 
More importantly for this discussion, ane-
mic patients treated with ESAs had higher 
odds of being in the upper two quartiles for 
the composite outcome of interleukin-6, 
interleukin-8, and tumor necrosis factor-α 
levels. One explanation for this finding 
would be that ESAs lead to a proinflam-
matory state and perhaps increase the risk 
for cardiovascular disease through this 
mechanism. However, as with the study of 
Szczech and colleagues,8 it is just as pos-
sible that the underlying comorbidities 
of patients treated with ESAs account for 
these findings (that is, those patients with 
more severe inflammation required ESAs 
(confounding by indication)). Further-
more, the use of iron and control of blood 
pressure may factor into these findings. 
In any case, the finding of higher levels 
of proinflammatory cytokines in patients 
treated with higher doses of ESAs leads to 
a testable hypothesis for the possible link 
between ESAs, higher hemoglobin targets, 
and increased risk of mortality.
Where do these two important studies 
leave us? At this time, a reasonable conclu-
sion would be that stated in the article by 
Szczech et al.:8 in patients unable to reach 
target hemoglobin levels, simply trying 
to continually increase ESA dosages to 
very high levels may be detrimental, and 
a limit to dose escalation should be con-
sidered. The mechanisms that account for 
this effect remain elusive, and future stud-
ies will need to be carefully designed to 
determine the specific contributions of the 
intertwining factors that probably account 
for the increased mortality associated 
with higher hemoglobin targets. Figure 
1 presents hypothetical factors that could 
be associated with the possible deleterious 
effects of supraphysiological doses of ESAs 
to achieve target hemoglobin levels in 
unresponsive patients. These parameters 
need to be examined in properly designed 
prospective controlled trials to assess their 
figure 1 | The interplay between factors potentially associated with the increased risk of 
mortality in CKD/ESRD patients targeted to higher hemoglobin levels. CKD, chronic kidney 
disease; ESA, erythropoietin-stimulating agent; ESRD, end-stage renal disease.
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individual and collective roles in leading 
to increased mortality risk. It is critically 
important for patients and caregivers to 
understand whether too much of a good 
thing (ESA therapy) may be harmful to 
our patients.
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Bone mass gain after 
parathyroidectomy
Andreas Pasch1
Yajima and co-workers investigated iliac bone biopsies taken before and 
after parathyroidectomy. They found enhanced de novo osteoid formation 
and mineral apposition at trabecular sites without signs of previous 
bone resorption. From this finding they conclude that ‘minimodeling’ 
contributes to the increase of bone volume following parathyroidectomy. 
This report refines our understanding of the compensatory mechanisms 
by which bone mass and possibly increased mechanical stability of the 
skeletal apparatus are regained after parathyroidectomy.
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Secondary hyperparathyroidism and 
the resulting bone disorder osteitis fib-
rosa are serious and common problems 
in long-term dialysis, affecting about 
20%–30% of patients.1 High levels of 
parathyroid hormone (PTH) are asso-
ciated with a loss of bone mass and an 
elevated risk of bone fractures.2 Before 
the invention of calcimimetics, surgi-
cal removal of the enlarged parathyroid 
glands was the treatment of choice for 
secondary hyperpara thyroidism. Sur-
gery results in a net gain of bone mass 
of 7%–23% in 3 years2 and a reduction 
of fracture risk.3
High serum levels of PTH stimulate 
the release of RANKL from osteoblasts/
stromal cells and thereby indirectly stimu-
late osteoclast differentiation and devel-
opment and increase bone resorption. In 
parallel, osteoblasts are activated to com-
pensate for this loss of bone mass by the 
formation of new bone tissue at sites of 
prior bone resorption. Unfortunately, this 
mechanism, called remodeling, does not 
suffice to make up for the lost bone mass.3
In addition to remodeling, the existence 
of yet another regenerative mechanism, 
called minimodeling, has been suspected 
on the basis of an early publication from 
1964,4 but only recently did it regain 
attention. Histologically, minimodeling is 
characterized by the presence of smooth 
cement lines, whereas in remodeling, 
scalloped cement lines are encountered, 
which indicate the previous bone-resorp-
tive action of osteoclasts.5 Accordingly, 
minimodeling is defined by an exclusion 
criterion, the de novo generation of bone 
tissue at trabecular sites without signs of 
prior bone resorption, which makes it at 
times difficult to unequivocally identify 
these sites.5 Modeling (shaping and grow-
ing of bone, visible without a microscope) 
and minimodeling (shaping and de novo 
growth of bone, visible by microscope 
only) have been shown to be the pre-
dominating mechanisms of bone mass 
gain in periods of bone growth. This was 
demonstrated in a very elegant experiment 
in rats performed by Erben.6 In this study, 
minimodeling accounted for about 60% 
of bone formation in the proximal tibial 
metaphysis in 3-month-old rats, whereas 
remodeling accounted for about 20%. In 
12-month-old rats, this ratio had changed, 
with remodeling present in about 66% and 
minimodeling in about 16% of sites. In 
accordance with the hypothesis proposed 
by Frost that minimodeling can also occur 
in adult life,7 minimodeling was encoun-
tered in 21 of 34 human iliac crest biopsies 
of non-uremic patients undergoing hip 
replacement.8 Likewise, minimodeling 
was found in iliac crest biopsies of adult 
hemodialysis patients with secondary 
hyperparathyroidism.9 Therefore, it has 
been hypothesized that minimodeling 
is a mechanism of bone formation that 
can be reactivated as an additional adap-
tive mechanism to size and shape bone 
